SPL UNCLASSIFIED SECTION
Homeopathic Arthritis Pain Relief Medicine
20 CAPSULES
Homeopathic Arthritis Pain Relief Medicine
20 CAPSULES
For temporary relief of cramped or aching muscles.
1 capsule contains 330 mg Propionibacterium avidum 6X in a base of lactose.
Capsule shells consist of Hypromellose (HPMC).
Do not use this product if imprinted inner blister pack is broken or if imprinted security strip on carton is torn.
1–2 times weekly, 1 capsule either before breakfaast or at bedtime.
If symptoms persist more than a few days, contact a licensed practitioner. As with any other drug, if you are pregnant or nursing a baby, seek the advice of a health care professional before taking this product.
Keep this and all other medications out of the reach of children. In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately.
Protect from light and heat.
Made in Germany
Distributed by:
SANUM USA Corp.
1465 Slater Road
Ferndale, WA 98248
Manufactured By:
Sanum-Kehlbeck
GmbH & Co. KG
Rev. 12/2006
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 60681-1601-1 | 2019-10-21 | C162847 | 48780-1 | 956f9ecf-d9dd-621f-e053-dbdaa90a74ad | Pleo™ Leptu CAPSULES 6X |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 60681-1601-1 | Pleo Leptu | 20 in 1 BLISTER PACK | CAPSULE | 20 | 1 | |
| 60681-1601-1 | Pleo Leptu | 1 in 1 CARTON | CAPSULE | 1 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 60681-1601 | PLEO LEPTU (PROPIONIBACTERIUM AVIDUM) CAPSULE [SANUM KEHLBECK GMBH & CO. KG] | 1 | Legacy NDC, 2 package rows | 20110113_8e25b263-3bda-45d2-9a80-9cb453d3bbb7.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| propionibacterium avidum | ACTIVE INGREDIENT | 29WQ1FER2K | 1 | |
| propionibacterium avidum | ACTIVE MOIETY | 29WQ1FER2K | 1 | |
| hypromellose | INACTIVE INGREDIENT | 3NXW29V3WO | 1 | |
| lactose | INACTIVE INGREDIENT | J2B2A4N98G | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 60681-1601 | 60681-1601-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| propionibacterium avidum | 29WQ1FER2K | ACTIB |
| lactose | J2B2A4N98G | IACT |
| hypromellose | 3NXW29V3WO | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| lactose | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | CAPSULE, COATED PELLETS / ORAL | 3.32 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE / RESPIRATORY (INHALATION) | 44.4 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SUSPENSION / OPHTHALMIC | 0.5 %w/w | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | POWDER / VAGINAL | 430 mg | ||
| lactose | LACTOSE | J2B2A4N98G | FILM, EXTENDED RELEASE / TRANSDERMAL | 675 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 221 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | GRANULE, FOR SUSPENSION / ORAL | 1.7 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v | ||
| lactose | LACTOSE | J2B2A4N98G | SUPPOSITORY / VAGINAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 193.8 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SUSPENSION/ DROPS / OPHTHALMIC | 3 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION / INTRAMUSCULAR | 203.5 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, DELAYED RELEASE / ORAL | 79 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | INSERT / VAGINAL | 54.21 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SUSPENSION / ORAL | 305 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, EXTENDED RELEASE / ORAL | 1472 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | CREAM / TOPICAL | 0.1 %w/w | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, COATED / ORAL | 58 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | CAPSULE / ORAL | 1488 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / RECTAL | 20 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SYSTEM / TOPICAL | 54 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | JELLY / TOPICAL | NA | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | GRANULE / ORAL | 45 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | GEL / RECTAL | 348 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, FILM COATED / ORAL | 582 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | CAPSULE, DELAYED RELEASE / ORAL | 105 mg | ||
| lactose | LACTOSE | J2B2A4N98G | OINTMENT / TOPICAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w | ||
| lactose | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | CAPSULE, EXTENDED RELEASE / ORAL | 119.7 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SOLUTION / OPHTHALMIC | 0.5 %w/v | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET / ORAL | 1127 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 133 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | LOTION / TOPICAL | 0.1 %w/w | ||
| lactose | LACTOSE | J2B2A4N98G | SOLUTION / RECTAL | 8 %w/v | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 133 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / BUCCAL | 296.7 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 133 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, CHEWABLE / ORAL | 11.8 mg | ||
| lactose | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| lactose | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION / INTRAVENOUS | 203.5 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SYRUP / ORAL | 250 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | SHAMPOO / TOPICAL | 3 %w/w | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | POWDER / RESPIRATORY (INHALATION) | 90 mg | ||
| hypromellose | HYPROMELLOSE | 3NXW29V3WO | TABLET, ORALLY DISINTEGRATING / ORAL | 41 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 60d43733-b29f-4dae-915e-a608e89aa2ae | 8e25b263-3bda-45d2-9a80-9cb453d3bbb7 | 2009-10-09 | Warnings | 60d43733-b29f-4dae-915e-a608e89aa2ae 8e25b263-3bda-45d2-9a80-9cb453d3bbb7 |
Adverse event summaries are temporarily unavailable. Other product information remains available.